Skip to main content

Table 1 Characteristics of the participants at baseline and 1st post-trial visit

From: Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study

Characteristics Baseline P 1st post-trial visit P
Fenofibrate (n = 484) Placebo (n = 456) Fenofibrate (n = 395) Placebo (n = 370)
Age 61.4 ± 6.2 62.2 ± 6.7 0.04 67.2 ± 6.3 67.6 ± 6.6 0.32
Sex 0.96    0.59
 Male 388 (80.2%) 364 (79.8%)   319 (80.8%) 292 (78.9%)  
 Female 96 (19.8%) 92 (20.2%)   76 (19.2%) 78 (21.1%)  
Years of diabetes 9.2 ± 6.6 9. 6 ± 6.6 0.37 14.6 ± 6.5 15.2 ± 6.6 0.22
Ethnicity 0.17    0.51
 White 365 (75.4%) 362 (79.4%)   305 (77.2%) 294 (79.5%)  
 Non-White 119 (24.6%) 94 (20.6%)   90 (22. 8%) 76 (20.5%)  
CVD history 0.93    0.98
 Yes 195 (40.3%) 186 (40.8%)   153 (38.7%) 142 (38.4%)  
 No 289 (59.7%) 270 (59.2%)   242 (61.3%) 228 (61.6%)  
BG trial assignment 0.36    0.36
 Intensive group 251 (51.8%) 222 (48.7%)   203 (51.4%) 177 (47.8%)  
 Standard group 233 (48.2%) 234 (51.3%)   192 (48.6%) 193 (52.2%)  
HbA1c (%) 8.4 ± 1.1 8.4 ± 1.0 0.94 7.9 ± 1.9 7.6 ± 1.3 0.07
SBP (mm Hg) 134.1 ± 17.6 133.9 ± 18.6 0.87 131.0 ± 17.1 131.8 ± 17.3 0.66
CHOL (mg/dl) 187.0 ± 38.5 189.0 ± 42.1 0.45 154.6 ± 42.5 152.8 ± 32.8 0.64
TG (mg/dl) 327.2 ± 125.3 325.0 ± 154.2 0.81 216.6 ± 124.1 222.7 ± 115.2 0.61
VLDL-C (mg/dl) 61.2 ± 18.6 61.2 ± 25.4 0.97 41.4 ± 20.8 42.63 ± 20.1 0.55
LDL-C (mg/dl) 96.3 ± 32.0 98.4 ± 32.9 0.34 79.2 ± 32.7 76.6 ± 26.1 0.38
HDL-C (mg/dl) 29.5 ± 3.8 29.5 ± 3.7 0.76 33.9 ± 7.3 33.6 ± 7.2 0.60
  1. Plus–minus values are mean ± SD
  2. HbA1c glycated hemoglobin A1c, SBP systolic blood pressure, CHOL total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, VLDL-C very low-density lipoprotein cholesterol